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BACKGROUND
The next-generation cystic fibrosis transmembrane conductance regulator (CFTR) 
corrector VX-659, in triple combination with tezacaftor and ivacaftor (VX-659–
tezacaftor–ivacaftor), was developed to restore the function of Phe508del CFTR 
protein in patients with cystic fibrosis.
METHODS
We evaluated the effects of VX-659–tezacaftor–ivacaftor on the processing, traffick-
ing, and function of Phe508del CFTR protein using human bronchial epithelial 
cells. A range of oral VX-659–tezacaftor–ivacaftor doses in triple combination were 
then evaluated in randomized, controlled, double-blind, multicenter trials involv-
ing patients with cystic fibrosis who were heterozygous for the Phe508del CFTR 
mutation and a minimal-function CFTR mutation (Phe508del–MF genotypes) or 
homozygous for the Phe508del CFTR mutation (Phe508del–Phe508del genotype). 
The primary end points were safety and the absolute change from baseline in the 
percentage of predicted forced expiratory volume in 1 second (FEV1).
RESULTS
VX-659–tezacaftor–ivacaftor significantly improved the processing and trafficking 
of Phe508del CFTR protein as well as chloride transport in vitro. In patients, VX-659–
tezacaftor–ivacaftor had an acceptable safety and side-effect profile. Most adverse 
events were mild or moderate. VX-659–tezacaftor–ivacaftor resulted in significant 
mean increases in the percentage of predicted FEV1 through day 29 (P<0.001) of 
up to 13.3 points in patients with Phe508del–MF genotypes; in patients with the 
Phe508del–Phe508del genotype already receiving tezacaftor–ivacaftor, adding VX-659 
resulted in a further 9.7-point increase in the percentage of predicted FEV1. The 
sweat chloride concentrations and scores on the respiratory domain of the Cystic 
Fibrosis Questionnaire–Revised improved in both patient populations.
CONCLUSIONS
Robust in vitro activity of VX-659–tezacaftor–ivacaftor targeting Phe508del CFTR 
protein translated into improvements for patients with Phe508del–MF or Phe508del–
Phe508del genotypes. VX-659 triple-combination regimens have the potential to 
treat the underlying cause of disease in approximately 90% of patients with cystic 
fibrosis. (Funded by Vertex Pharmaceuticals; VX16-659-101 and VX16-659-001 
ClinicalTrials.gov numbers, NCT03224351 and NCT03029455.)
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Cystic fibrosis is a serious, autosomal-recessive, multisystem disease that affects approximately 80,000 people worldwide 
and is associated with early death due to pro-
gressive lung disease.1,2 Cystic fibrosis is caused 
by diminished quantity and defective function of 
an epithelial anion channel, the cystic fibrosis 
transmembrane conductance regulator (CFTR), 
as a consequence of mutations in CFTR.3,4 For 
approximately 60% of patients with cystic fibro-
sis (i.e., those with two Phe508del alleles or a 
gating or residual-function CFTR mutation), small-
molecule CFTR modulators provide therapeutic 
benefit by restoring CFTR activity.5 However, 
high levels of chloride-transport restoration have 
not been achieved for the majority of patients 
with cystic fibrosis, approximately 90% of whom 
are either homozygous or heterozygous for the 
Phe508del CFTR mutation.6 There are currently 
no approved CFTR modulators to treat the esti-
mated 30% of patients who are heterozygous for 
the Phe508del CFTR mutation and a minimal-
function CFTR mutation (Phe508del–MF geno-
types), which leaves a substantial portion of the 
patient population without a treatment address-
ing the basic defect.7-9
The Phe508del CFTR mutation causes severe 
processing and trafficking defects, which result 
in decreased quantity and function of CFTR pro-
tein at the cell surface,4 and has proven to be a 
challenging molecular target. Among patients 
who have at least one Phe508del CFTR mutation, 
approximately half have a second Phe508del allele 
(Phe508del–Phe508del genotype), and one third 
have a minimal-function CFTR mutation as the 
second allele. Minimal-function mutations, which 
produce either no protein or a defective protein 
that is unresponsive to CFTR modulators, in-
clude nonsense mutations, insertion and deletion 
mutations, canonical splicing mutations, and 
certain severe protein misfolding mutations.1 A 
CFTR modulator regimen that could achieve 
high levels of functional CFTR in patients with 
a Phe508del allele, regardless of whether the 
second CFTR allele is also responsive to CFTR 
modulator therapy (e.g., a second Phe508del allele) 
or is incapable of response (i.e., the allele contains 
a minimal-function mutation), would be of value.
On the basis of the well-established under-
standing of the molecular defects caused by the 
Phe508del CFTR mutation, two complementary 
approaches have been developed to restore chlo-
ride transport by increasing the quantity and 
function of Phe508del CFTR protein at the cell 
surface. CFTR correctors, such as lumacaftor and 
tezacaftor, bind the Phe508del CFTR protein, 
augmenting intracellular processing and traffick-
ing and thereby increasing the amount of ma-
ture CFTR available at the cell surface. The CFTR 
potentiator ivacaftor increases the channel-gating 
activity of Phe508del CFTR protein that is deliv-
ered to the cell surface, to augment anion trans-
port.10 With differing mechanisms of action, the 
combination of CFTR correctors and a CFTR po-
tentiator is required to increase both the amount 
and function of Phe508del CFTR protein and is 
more effective than either approach alone.10
For patients with the Phe508del–Phe508del 
genotype, dual combinations of a first-generation 
CFTR corrector (lumacaftor or tezacaftor) and 
ivacaftor provide both short-term and long-term 
clinical benefit and are now accepted as the 
standard of care.11 Nonetheless, these dual combi-
nations do not fully restore function to Phe508del 
CFTR protein and are not sufficiently active to 
improve outcomes in patients with Phe508del–MF 
genotypes. As a consequence, there remains a 
need for highly effective CFTR modulation that 
will more adequately treat the underlying cause 
of disease in most patients with cystic fibrosis.12-14
We have previously shown in vitro that a com-
bination of two correctors with distinct binding 
sites on CFTR and complementary mechanisms 
of action can increase the amount of Phe508del 
CFTR protein at the cell surface to a greater ex-
tent than either corrector alone.15 On the basis 
of these findings, we developed next-generation 
CFTR correctors for use in combination with 
tezacaftor–ivacaftor to increase both the amount 
and function of Phe508del CFTR protein to a 
greater extent than a dual combination of a cor-
rector and a potentiator. VX-659, a next-genera-
tion corrector, has both a different structure and 
a different mechanism of action. Its distinct 
mechanism of action is based on clear additivity 
on functional and biochemical assays of CFTR 
processing, trafficking, and function in vitro. 
Additivity of VX-659 to tezacaftor and ivacaftor 
in vitro increases Phe508del CFTR protein pro-
cessing within the cell and trafficking to the cell 
surface. VX-659 shares some structural similar-
ity and a mechanism of action with the next-
generation corrector VX-445, described in a com-
panion report also appearing in the Journal.16 
Because tezacaftor and VX-659 work through 
different mechanisms, we hypothesized that the 
The New England Journal of Medicine 
Downloaded from nejm.org at University College Cork - IREL on February 21, 2020. For personal use only. No other uses without permission. 
 Copyright © 2018 Massachusetts Medical Society. All rights reserved. 
n engl j med 379;17 nejm.org October 25, 2018 1601
VX-659–Tezacaftor–Ivacaftor in Cystic Fibrosis
combination of VX-659 and tezacaftor would 
increase the amount of Phe508del CFTR protein 
at the cell surface more than either compound 
alone, an effect that could be potentiated by 
ivacaftor to further increase chloride transport.
We evaluated the effect of the VX-659–
tezacaftor–ivacaftor triple combination on the pro-
cessing, trafficking, and function of Phe508del 
CFTR protein in airway epithelial cells, which 
are an important and predictive preclinical mod-
el in cystic fibrosis.10 These cells were obtained 
from patients with Phe508del–MF or Phe508del–
Phe508del genotypes. We then conducted a small, 
phase 1 trial involving patients, followed by a 
larger, phase 2, proof-of-concept trial to evaluate 
the safety and efficacy of a range of VX-659 triple-
combination doses in patients with one or two 
Phe508del alleles. For patients with Phe508del–
MF genotypes, there is no available CFTR modu-
lator, whereas for patients with the Phe508del–
Phe508del genotype the standard of care includes 
a two-drug CFTR modulator combination; as a 
consequence, the trial designs differed accord-
ing to patient genotype.
Me thods
Preclinical Development
The in vitro pharmacologic characteristics of 
VX-659 were evaluated in biochemical and func-
tional studies alone and in dual and triple com-
bination with tezacaftor–ivacaftor with the use 
of human bronchial epithelial cells derived from 
patients with cystic fibrosis and Phe508del–
MF genotypes (four donors) or the Phe508del–
Phe508del genotype (three donors). For details, 
see the Methods section in the Supplementary 
Appendix (available with the full text of this arti-
cle at NEJM.org).
Clinical Development
Trial Design and Oversight
A randomized, placebo-controlled, double-blind, 
multicenter, phase 1 trial (VX16-659-001) was 
conducted to evaluate preliminary pharmacoki-
netics and initial safety in a small group of pa-
tients with cystic fibrosis (Fig. 1). This trial en-
rolled patients 18 years of age or older with 
cystic fibrosis and Phe508del–MF CFTR genotypes 
and was conducted at nine sites in the United 
Kingdom from April 2017 through July 2017. 
Patients were randomly assigned, in a 2:1 ratio, 
to receive 14 days of active treatment with oral 
VX-659 at a dose of 120 mg every 12 hours in 
combination with tezacaftor (100 mg once daily) 
and ivacaftor (150 mg every 12 hours) or to re-
ceive oral triple placebo in parallel cohorts. Triple 
placebo was used as the control in this and sub-
sequent trials involving patients with Phe508del–
MF genotypes because these patients currently 
lack an approved standard-of-care CFTR modu-
lator regimen.
After the phase 1 trial, a randomized, parallel-
track, placebo- or active-controlled, double-blind, 
multicenter, dose-ranging, phase 2 trial (VX16-
659-101) was conducted with multiple dose levels 
of VX-659 (Fig. 1). This trial enrolled patients 
18 years of age or older with cystic fibrosis and 
Phe508del–MF or Phe508del–Phe508del CFTR 
genotypes. The phase 2 trial was conducted at 48 
sites in the United States, the United Kingdom, 
Ireland, and Israel from August 2017 through 
February 2018.
The VX16-659-101 trial had three parts. In the 
first part, patients with Phe508del–MF genotypes 
were assigned to receive 4 weeks of active treat-
ment with oral VX-659 at doses of 80, 240, or 
400 mg once daily in triple combination with 
tezacaftor (100 mg once daily) and ivacaftor 
(150 mg every 12 hours) or to receive oral triple 
placebo in parallel cohorts. A randomization ratio 
of 1:2:2:1 was used to decrease the variability and 
thus increase the accuracy of the within-group 
efficacy estimate for the intermediate- and high-
dose levels, at which the efficacy was predicted 
to plateau. This intervention period was followed 
by 4 days of only tezacaftor–ivacaftor (washout 
of VX-659) for those who had received active 
triple-combination therapy.
In the second part of the trial, patients with 
the Phe508del–Phe508del genotype were recruited. 
Because dual-combination CFTR modulators are 
the standard of care for these patients, tezacaftor–
ivacaftor was used as the active control. Patients 
received 4 weeks of oral tezacaftor–ivacaftor 
during a run-in period, followed by randomiza-
tion (in a 2:1 ratio) to 4 weeks of either oral 
VX-659 (400 mg once daily) or matched placebo 
in combination with tezacaftor–ivacaftor. This 
intervention period was followed by 4 weeks of 
tezacaftor–ivacaftor only (washout of VX-659). 
Baseline status for efficacy end points was as-
sessed at the time of randomization, when all 
patients with the Phe508del–Phe508del genotype 
had been receiving daily tezacaftor–ivacaftor for 
at least 28 days.
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The third part of the VX16-659-101 trial in-
volved patients with Phe508del–MF genotypes 
who received VX-659–tezacaftor–VX-561 or triple 
placebo. VX-561 is a deuterated form of the 
CFTR potentiator ivacaftor that is administered 
orally once daily; the nondeuterated form of 
ivacaftor is administered twice daily. For details, 
see the Methods section in the Supplementary 
Appendix.
For both the VX16-659-001 and VX16-659-101 
trials, the trial protocols and informed-consent 
forms were approved by an independent ethics 
committee or institutional review board at each 
trial site. All enrolled patients provided written 
informed consent. Safety was monitored by an 
independent data and safety monitoring com-
mittee. The trials were designed by the sponsor, 
Vertex Pharmaceuticals, in collaboration with the 
authors. Data gathering and analysis were per-
formed by Vertex Pharmaceuticals in collabora-
tion with the authors and the VX16-659-001 and 
VX16-659-101 Study Groups. All the authors had 
full access to the trial data after the data were 
unblinded and provided critical review and input 
on the manuscript. The first draft of the manu-
script was written by an author employed by the 
sponsor with the assistance of medical writers 
funded by the sponsor. Final decisions regarding 
the content of the submitted manuscript were 
made by the first and last authors, and all the 
authors made the decision to submit the manu-
script for publication. The investigators vouch 
for the accuracy and completeness of the data 
generated at their respective institutions, and the 
investigators and Vertex Pharmaceuticals vouch 
for the fidelity of the trials to the protocols. 
Confidentiality agreements were in place between 
the sponsor and all investigators during the trials. 
Trial protocols, along with the statistical analy-
sis plans, are available at NEJM.org (Protocol 1 
[VX16-659-001] and Protocol 2 [VX16-659-101]).
Trial Participants
In addition to the characteristics described above, 
patients eligible for inclusion had a percentage 
of predicted forced expiratory volume in 1 sec-
ond (FEV1) of 40 to 90% at screening
17 and stable 
disease as determined by the investigator on the 
basis of clinical assessment, including cystic fi-
brosis symptoms and treatment during the 28 days 
before the first dose of the trial regimen. Inclu-
sion and exclusion criteria and the equations 
used to determine each patient’s percentage of 
predicted FEV1 are provided in the Methods sec-
tion in the Supplementary Appendix.
Phase 1 Trial Assessments
The primary end points were safety and side-
effect profile, based on the assessment of ad-
verse events, clinically significant laboratory-test 
results, standard 12-lead electrocardiograms, vital 
signs, and spirometric measurements.
Phase 2 Trial Assessments
The primary end points were safety, side-effect 
profile, and the absolute change in the percent-
age of predicted FEV1 from baseline through day 
29. Safety assessments included adverse events, 
clinical laboratory values, electrocardiograms, and 
vital signs. Summarized safety data were based 
on events observed during the interval from the 
first dose of the trial regimen to 28 days after 
the last dose of the trial regimen or the end of 
the trial, whichever occurred first. Secondary 
end points included the absolute change in sweat 
chloride concentration from baseline through 
day 29 and the absolute change from baseline in 
Cystic Fibrosis Questionnaire–Revised (CFQ-R) 
respiratory domain score at day 29. Scores range 
from 0 to 100, with higher scores indicating a 
higher patient-reported quality of life with re-
Figure 1 (facing page). Trial Design and Randomization 
and Follow-up of Patients.
Panel A shows the design of the phase 1 trial (VX16-
659-001) and phase 2 trial (VX16-659-101) involving 
patients who were heterozygous for the Phe508del 
CFTR mutation and a minimal-function CFTR mutation 
(Phe508del–minimal function genotypes) and patients 
who were homozygous for the Phe508del CFTR muta-
tion (Phe508del–Phe508del genotype). In the phase 1 
trial, the dose of VX-659 was 120 mg every 12 hours; 
tezacaftor–ivacaftor (TEZ–IVA) was administered at a 
dose of 100 mg of TEZ once daily and 150 mg of IVA 
every 12 hours. In the phase 2 trial, the dose of VX-659 
shown is the dose that was administered once daily; 
TEZ–IVA was administered at the same dose as in the 
phase 1 trial. A subgroup of patients with the Phe508del–
minimal function genotype received VX-561 once daily 
instead of IVA every 12 hours. In the phase 2 trial, period 
1 is the 4-week intervention period; period 2 is a wash-
out of VX-659, as applicable. Panel B shows the number 
of patients in each intervention group who received  
at least one dose of the trial regimen and the number 
who completed the intervention period of 2 weeks 
(phase 1 trial) or 4 weeks (phase 2 trial).
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spect to respiratory status (minimal clinically 
important difference, 4 points).
Statistical Analysis
For both the phase 1 and 2 trials, the intention-
to-treat population, which included all the pa-
tients who received at least one dose of the trial 
regimen and had the intended CFTR mutation, 
was used to analyze the efficacy outcomes. The 
safety population, which included all the patients 
who received at least one dose of the trial regi-
men, was used for all safety analyses. For the 
phase 1 trial, efficacy end points, including the 
absolute change from baseline in the percentage 
of predicted FEV1 and sweat chloride concentra-
tion, were summarized with the use of descrip-
tive statistics.
For the phase 2 trial, safety data from patients 
receiving VX-659–tezacaftor–ivacaftor who had 
Phe508del–MF or Phe508del–Phe508del geno-
types were pooled for the safety analysis. The 
primary end point of the absolute change from 
baseline in the percentage of predicted FEV1 was 
analyzed separately for each part of the trial 
with the use of a mixed-effects model for re-
peated measures, with the change from baseline 
in the percentage of predicted FEV1 at days 15 
and 29 as the dependent variable. The within-
group estimate along with the 95% confidence 
intervals and the corresponding P values were 
calculated as the primary analysis. Secondary end 
points, including sweat chloride concentration 
and CFQ-R respiratory domain score, were ana-
lyzed similarly, and the within-group estimate 
and 95% confidence intervals were calculated. 
The widths of the confidence intervals have not 
been adjusted for multiple comparisons and the 
intervals should not be used to infer definitive 
treatment effects. The primary analysis for all 
efficacy end points was the within-group com-
parison. (Additional details of the statistical 
analysis are provided in the Methods section and 
Table S1 in the Supplementary Appendix.)
R esult s
In Vitro Efficacy in Primary Human Bronchial 
Epithelial Cells
VX-659 improved the processing and trafficking of 
Phe508del CFTR protein in human bronchial epi-
thelial cells derived from patients with Phe508del–
MF or Phe508del–Phe508del genotypes, as shown 
by higher steady-state levels of mature CFTR 
protein than in controls (Fig. 2A and 2B). The 
combination of VX-659–tezacaftor without or 
with ivacaftor resulted in significantly higher 
steady-state levels of mature CFTR protein than 
either compound alone. Ivacaftor slightly reduced 
the magnitude of CFTR processing correction by 
VX-659–tezacaftor in human bronchial epithelial 
cells from patients with the Phe508del–Phe508del 
genotype; however, correction by the triple com-
bination was greater than that observed after 
treatment with dual combinations of either 
tezacaftor–ivacaftor or VX-659–ivacaftor.
Untreated human bronchial epithelial cells 
from patients with Phe508del–MF or Phe508del–
Phe508del genotypes showed minimal CFTR-
mediated chloride transport, a finding consis-
tent with little to no functional CFTR at the cell 
surface (Fig. 2C). Treatment with VX-659 alone 
produced a modest increase in chloride trans-
port, which was further augmented by combina-
tion with tezacaftor, ivacaftor, or both. The great-
est increase in chloride transport was observed 
with the triple combination of VX-659–tezacaftor–
ivacaftor (Fig. 2C). Together, these in vitro studies 
provided the rationale for investigating a triple-
combination regimen of two correctors, VX-659 
and tezacaftor, with the CFTR potentiator iva-
caftor in patients with cystic fibrosis with either 
Phe508del–MF or Phe508del–Phe508del geno-
types.
VX-659–Tezacaftor–Ivacaftor in Patients 
with Cystic Fibrosis
Patient Population
As part of a phase 1 trial (VX16-659-001) in 
which safety and pharmacokinetics were initially 
shown in healthy volunteers, we evaluated pre-
liminary safety and pharmacokinetics of VX-659–
tezacaftor–ivacaftor in a cohort of 12 patients 
with cystic fibrosis with Phe508del–MF genotypes. 
Patients were randomly assigned to receive either 
VX-659–tezacaftor–ivacaftor (9 patients) or triple 
placebo (3 patients) (Fig. S1 and Tables S2 
through S5 in the Supplementary Appendix).
In the subsequent phase 2 trial, 117 patients 
with cystic fibrosis and Phe508del–MF genotypes 
(88 patients) or the Phe508del–Phe508del geno-
type (29 patients) were randomly assigned to 
receive either a VX-659 triple-combination regi-
men containing ivacaftor (71 patients) or VX-561 
(19 patients) or a control regimen (27 patients) 
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(Fig. 1). A total of 115 patients completed the 
4-week intervention period.
Baseline age, sex, percentage of predicted FEV1, 
and sweat chloride concentration were generally 
well balanced across genotype and intervention 
groups (Table 1, and Table S6 [VX-659–tezacaftor–
ivacaftor] and Table S7 [VX-659–tezacaftor–VX-
561] in the Supplementary Appendix). For patients 
with Phe508del–MF genotypes who received 
VX-659–tezacaftor–ivacaftor or triple placebo, 
the mean baseline CFQ-R respiratory domain 
score was numerically higher in the placebo 
group than in the active-treatment groups (dif-
ference, 12.6 to 14.1 points). Consequently, analy-
sis of the change in the CFQ-R respiratory do-
main score was performed both with and without 
adjustment for the baseline score (see the Methods 
section in the Supplementary Appendix for de-
tails).
 Phase 1 Trial
The most common adverse events with VX-659–
tezacaftor–ivacaftor were cough, infective pulmo-
nary exacerbation of cystic fibrosis, and produc-
tive cough (each occurred in two patients). Oral 
candidiasis occurred in one patient in the VX-659–
tezacaftor–ivacaftor group and one in the placebo 
group. Most adverse events were mild or moder-
ate, and none led to interruption or discontinua-
tion of the trial regimen. Two serious adverse 
events of infective pulmonary exacerbation of 
cystic fibrosis occurred in the VX-659–tezacaftor–
ivacaftor group, one mild and one moderate in 
severity; both events occurred after the end of 
dosing (Table S3 in the Supplementary Appendix).
Figure 2. In Vitro Effect of VX-659 Alone or in Combination 
with TEZ, IVA, or TEZ–IVA.
Panels A and B show the effect of VX-659 on the pro-
cessing and trafficking of Phe508del CFTR protein in 
human bronchial epithelial (HBE) cells derived from 
patients with Phe508del–minimal function (Phe508del–
MF) or Phe508del–Phe508del genotypes. Panel A shows 
the results of representative immunoblotting from three 
independent experiments. Panel B shows the quanti-
tative assessment of that data through densitometry 
findings pooled from three independent experiments, 
with six replicates in each experiment. Data are pre-
sented as mean relative intensities normalized to cal-
nexin, a control for protein loading. The compound 
concentrations used were as follows: 1.4 μM of VX-659, 
18 μM of TEZ, and 1 μM of IVA in the presence of 10 
mg per milliliter of human serum albumin. The letter 
a represents P<0.05 for the comparison with vehicle, 
b P<0.05 for the comparison with TEZ–IVA, and c P<0.05 
for the comparison with VX-659 in unpaired t-tests. 
Panel C shows an assessment of chloride transport in 
HBE cells treated with various combinations of TEZ 
(18 μM), IVA (1 μM), and VX-659 (1 μM) by means of 
an Ussing chamber. Data represent the mean of three 
or four donor bronchi, with three or four replicate ex-
periments per donor. The letter x represents P<0.05 
for the comparison with vehicle, y P<0.05 for the com-
parison with TEZ–IVA, and z P<0.05 for the comparison 
with VX-659–IVA in paired t-tests. In Panels B and C, 
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VX-659–tezacaftor–ivacaftor therapy resulted 
in substantial improvements in the percentage of 
predicted FEV1 and sweat chloride concentration 
(Fig. S1 and Table S5 in the Supplementary Ap-
pendix). These improvements were not seen in 
patients who received triple placebo.
Phase 2 Safety
Most patients who received VX-659–tezacaftor–
ivacaftor (57 of 71 patients [80%]), triple placebo 
(9 of 10 [90%]), or tezacaftor–ivacaftor (9 of 11 
[82%]) reported having at least one adverse event 
(Table 2, and Table S8 in the Supplementary 
Appendix). Among those receiving VX-659–
tezacaftor–ivacaftor who had an adverse event, 
the maximum severity was mild or moderate for 
the majority of patients (53 of 57 patients [93%]). 
The most commonly observed adverse events 
(>10% occurrence in the pooled VX-659–teza-
caftor–ivacaftor groups) were cough, infective 
pulmonary exacerbation of cystic fibrosis, head-
ache, oropharyngeal pain, and increased sputum 
production. Four adverse events in patients receiv-
ing VX-659–tezacaftor–ivacaftor therapy were 
considered to be severe by site investigators 
(Table 2). Serious adverse events were reported 
in 7 patients (10%) who received VX-659–
tezacaftor–ivacaftor, 3 patients (30%) who re-
ceived triple placebo, and 2 patients (18%) who 
received tezacaftor–ivacaftor control. Most seri-
ous adverse events were infective pulmonary 
exacerbations of cystic fibrosis requiring hospi-
talization. No deaths occurred during the trial. 
There were no adverse events leading to discon-
tinuation of the trial regimen in any patients 
who received VX-659–tezacaftor–ivacaftor.
One patient interrupted VX-659–tezacaftor–
ivacaftor because of a rash. The rash resolved, and 
the patient resumed the trial regimen and com-
pleted the trial without recurrence of the rash. 
Two patients who received VX-659–tezacaftor–
ivacaftor had elevations of alanine aminotrans-
ferase or aspartate aminotransferase levels (>3 to 
≤5 times the upper limit of the normal range in 
one patient and >5 to ≤8 times the upper limit 
of the normal range in one patient) without con-
current elevation in the bilirubin level (Table S9 
in the Supplementary Appendix). The elevations 
resolved during the trial without interruption 
of the trial regimen. There was no evidence of 
bronchoconstriction after VX-659 triple-combi-
nation dosing in any genotype or lung-function 
category as assessed by post-dose spirometry. The 
safety profile of VX-659–tezacaftor–VX-561 was 
similar to that of VX-659–tezacaftor–ivacaftor 
(Tables S10 and S11 in the Supplementary Ap-
pendix).
Phase 2 Efficacy
All doses of VX-659–tezacaftor–ivacaftor result-
ed in significant improvement in the percentage 
of predicted FEV1 as compared with the respec-




VX-659, 80 mg, 
+ TEZ–IVA 
(N = 11)
VX-659, 240 mg, 
+ TEZ–IVA 
(N = 20)






VX-659, 400 mg, 
+ TEZ–IVA 
(N = 18)
Male sex — no. (%) 6 (60) 4 (36) 13 (65) 10 (45) 7 (64) 12 (67)
Age — yr 26.6±6.0 32.0±11.7 31.4±9.7 27.2±6.6 32.5±7.5 33.4±9.2
Percentage of predicted FEV1 53.9±12.0 57.9±10.8 58.0±16.8 59.6±15.4 60.0±12.6 58.6±13.3
Sweat chloride — mmol/liter 98.2±13.3 102.7±7.0 100.5±9.0 100.7±11.6 96.6±11.4 91.9±11.6
CFQ-R respiratory domain score‡ 77.2±15.1 63.1±18.5 64.4±17.8 64.6±20.7 65.7±17.4 68.5±14.1
*  Plus–minus values are means ±SD. Patients with Phe508del–minimal function genotypes were heterozygous for the Phe508del CFTR muta-
tion and a minimal-function CFTR mutation, and those with the Phe508del–Phe508del genotype were homozygous for the Phe508del CFTR 
mutation. All baseline characteristics were tested for balance between groups with the use of Fisher’s exact test for categorical variables and 
the F test for all other variables. There were no significant differences between the intervention groups. The dose of VX-659 is the dose that 
was administered once daily. Tezacaftor–ivacaftor (TEZ–IVA) was administered at a dose of 100 mg of TEZ once daily and 150 mg of IVA 
every 12 hours. FEV1 denotes forced expiratory volume in 1 second.
†  The baseline characteristics of patients with the Phe508del–Phe508del genotype were assessed after a 4-week run-in with TEZ–IVA.
‡  Scores on the respiratory domain of the Cystic Fibrosis Questionnaire–Revised (CFQ-R) range from 0 to 100, with higher scores indicating a 
higher patient-reported quality of life with respect to respiratory status (minimal clinically important difference, 4 points).
Table 1. Baseline Demographic and Clinical Characteristics of the Phe508del–Minimal Function and Phe508del–Phe508del Cohorts.*
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tive within-group baseline values in patients with 
Phe508del–MF or Phe508del–Phe508del geno-
types (Table 3). These improvements were ob-
served at the first assessment on day 15 and 
were sustained at day 29 (Fig. 3). Changes indi-
cating a beneficial effect of VX-659–tezacaftor–
ivacaftor were observed for the secondary end 
points of sweat chloride concentration and the 
CFQ-R respiratory domain score, findings con-
sistent with the magnitude of improvement in 
the percentage of predicted FEV1 (Fig. 3 and 
Table 3). Improvement in the CFQ-R respiratory 
domain score at day 29 was observed with or 
without adjustment for the baseline score (Ta-
ble 3 [without adjustment], and Table S12 in the 
Supplementary Appendix [with adjustment]). Data 
on the absolute and relative changes in FEV1 as 
a percentage of the predicted value and in liters 
are provided in Table S12 in the Supplementary 
Appendix. Individual patient data for the abso-
lute change from baseline in the percentage of 
predicted FEV1 and sweat chloride concentration 
at day 29 are included in Figure S2 in the Supple-
mentary Appendix. Similar improvements in all 
these end points were observed in patients with 
Phe508del–MF genotypes who received VX-659–
tezacaftor–VX-561 (Table S13 and Fig. S3 in the 
Supplementary Appendix).
Discussion
In our in vitro to in vivo studies, the next-genera-
tion CFTR corrector VX-659 in combination with 




VX-659, 80 mg, 
+ TEZ–IVA 
(N = 11)
VX-659, 240 mg, 
+ TEZ–IVA 
(N = 20)






VX-659, 400 mg, 
+ TEZ–IVA 
(N = 18)
Percentage of predicted FEV1
Absolute change from baseline 0.4±2.8 10.2±2.7 12.0±2.0 13.3±1.9 0.0±1.9 9.7±1.5
95% CI −5.3 to 6.1 4.8 to 15.5 8.0 to 16.0 9.5 to 17.1 −3.9 to 3.9 6.6 to 12.7
P value† 0.90 <0.001 <0.001 <0.001 0.99 <0.001
Sweat chloride — mmol/liter
Absolute change from baseline 2.9±4.6 −45.7±4.3 −43.8±3.4 −51.4±3.2 3.0±2.8 −42.2±2.2
95% CI‡ −6.3 to 12.2 −54.4 to −37.0 −50.7 to −37.0 −57.8 to −44.9 −2.8 to 8.9 −46.8 to −37.7
CFQ-R respiratory domain score§
Absolute change from baseline 4.7±6.1 24.6±5.8 19.8±4.4 21.8±4.1 2.9±4.0 19.5±3.1
95% CI‡ −7.5 to 16.8 13.0 to 36.2 11.0 to 28.6 13.6 to 30.0 −5.2 to 11.1 13.1 to 25.9
*  Plus–minus values are least-squares means ±SE. Data were analyzed with the use of a mixed-effects model with repeated measures. CI de-
notes confidence interval.
†  Shown is the within-group P value for the comparison with baseline.
‡  The widths of the confidence intervals have not been adjusted for multiple comparisons, and the intervals should not be used to infer defin-
itive treatment effects.
§  Values for CFQ-R respiratory domain score were not adjusted for baseline score; a prespecified analysis with adjustment for baseline CFQ-R 
respiratory domain score is presented in Table S12 in the Supplementary Appendix.
Table 3. Absolute Change from Baseline in the Percentage of Predicted FEV1 and Sweat Chloride Concentration through Day 29 and CFQ-R 
Respiratory Domain Score at Day 29.*
Figure 3 (facing page). Absolute Change from Baseline 
in the Percentage of Predicted FEV1, Sweat Chloride 
Concentration, and CFQ-R Respiratory Domain Score.
Shown is the least-squares mean change in the percent-
age of predicted forced expiratory volume in 1 second 
(FEV1) though day 29, sweat chloride concentration 
through day 29, and score on the respiratory domain of 
the Cystic Fibrosis Questionnaire–Revised (CFQ-R), with-
out adjustment for baseline scores, at day 29 in patients 
with Phe508del–minimal function genotypes (Panel A) 
and those with the Phe508del–Phe508del genotype 
(Panel B). CFQ-R respiratory domain scores range from 
0 to 100, with higher scores indicating a higher patient-
reported quality of life with respect to respiratory status 
(minimal clinically important difference, 4 points). I bars 
indicate standard errors. Asterisks indicate a within-group 
P value of less than 0.001 for the comparison with base-
line. TC denotes triple-combination therapy with  
VX-659–TEZ–IVA; the dose in milligrams represents  
the dose of VX-659 administered once daily.
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tezacaftor–ivacaftor led to improvements in CFTR 
activity and in measures of lung function and 
quality of life in patients with cystic fibrosis and 
Phe508del–MF or Phe508del–Phe508del geno-
types. In these phase 1 and phase 2 trials with 
intervention periods of 2 to 4 weeks, no dose-
limiting side effects or toxic effects were noted 
with administration of VX-659. Most notably, pa-
tients with Phe508del–MF genotypes, who have 
only one responsive Phe508del allele and no 
currently available CFTR modulator therapy, had 
improvements in lung function, sweat chloride 
concentration, and CFQ-R respiratory domain 
score. In addition, patients with the Phe508del–
Phe508del genotype who were already receiving 
tezacaftor–ivacaftor had additional improvements 
in these outcome measures after the administra-
tion of VX-659. Thus, these trials of VX-659–
tezacaftor–ivacaftor pave the way for larger and 
longer trials of the clinical usefulness of triple-
combination CFTR modulator regimens for pa-
tients with cystic fibrosis who have one or two 
copies of the Phe508del CFTR mutation.
Treatment with VX-659–tezacaftor–ivacaftor led 
to an average absolute increase in the percentage 
of predicted FEV1 of up to 13.3 points in patients 
with Phe508del–MF genotypes, as compared with 
baseline values. In patients with the Phe508del–
Phe508del genotype who were already receiving 
tezacaftor–ivacaftor, the addition of VX-659 re-
sulted in an average absolute increase in the per-
centage of predicted FEV1 of 9.7 points. The re-
sponse with respect to lung function was largely 
apparent at the first assessment after the start of 
treatment and was sustained throughout the 
4-week trial, findings consistent with the timing 
of responses observed with other effective CFTR 
modulator regimens.12-14,18,19 The increases in the 
percentage of predicted FEV1 were accompanied 
by improvements in sweat chloride concentration, 
an in vivo measure of CFTR function, and in the 
CFQ-R respiratory domain score, a patient-reported 
measure of respiratory symptoms.12-14 Treatment 
with the alternative once-daily regimen of VX-659–
tezacaftor–VX-561 led to similar improvements 
in patients with Phe508del–MF genotypes.
The clinical efficacy of VX-659–tezacaftor–
ivacaftor that was noted in the phase 2 trial was 
clearly predicted by the in vitro cell-based bio-
assay. In vitro, we found that including all three 
components of the triple combination led to the 
largest effects on CFTR protein levels and chlo-
ride transport in cells from donors with either 
Phe508del–MF or Phe508del–Phe508del genotypes, 
with VX-659 adding substantially to the com-
bined effect of tezacaftor and ivacaftor. More-
over, VX-659–tezacaftor–ivacaftor increased chlo-
ride transport in such cells more effectively than 
the dual combination of VX-659–ivacaftor and 
more than the individual agents alone. The mag-
nitude of improvement in chloride transport in 
cells from patients with Phe508del–MF geno-
types that were treated with VX-659–tezacaftor–
ivacaftor reached approximately 50% of wild-type 
CFTR activity, an effect similar to that of ivacaftor 
in cells from patients with CFTR gating muta-
tions.20 On the basis of these data, the clinical 
effect of the triple-combination regimen in pa-
tients with at least one Phe508del allele was pre-
dicted to be similar to the effect of ivacaftor in 
patients with gating mutations,18 and the subse-
quent clinical-trial results substantiated this pre-
diction.
These trials of relatively short duration re-
vealed no concerning safety signals across the 
genotype groups and range of VX-659 triple-
combination doses studied. The majority of pa-
tients had adverse events that were mild or mod-
erate in severity, and there were a limited number 
of interruptions or discontinuations of the trial 
regimen due to adverse events; no dose relation-
ship was seen for these events. Overall, the safety 
profile of VX-659 triple-combination therapy was 
similar to that seen in previous studies of CFTR 
modulators.12-14,18,19 In addition, two other com-
ponents of the triple combination, tezacaftor and 
ivacaftor, have well-characterized safety profiles 
in short-term and long-term studies.13,14,21,22
In conclusion, we found that VX-659 triple-
combination therapy led to improvements in all 
evaluated efficacy outcomes in patients with 
cystic fibrosis and Phe508del–MF or Phe508del–
Phe508del genotypes. An additive response was 
seen for VX-659 triple-combination therapy in com-
parison with the dual combination of tezacaftor–
ivacaftor in patients with the Phe508del–Phe508del 
genotype. These trials provide proof of the con-
cept that targeting the Phe508del CFTR protein 
with a triple-combination corrector–potentiator 
regimen can restore CFTR function and has the 
potential to represent a clinical advance for pa-
tients with cystic fibrosis who harbor either one 
or two Phe508del alleles, approximately 9 of every 
10 patients with the disease.
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